http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis
-
Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis
-
Viatris Inc (VTRS) Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141
-
Viatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia
-
VTRS DEADLINE ALERT: ROSEN, LEADING INVESTOR COUNSEL, Encourages Viatris Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 3 Deadline in Securities Class Action - V
-
Viatris Inc (VTRS) Announces Positive Top-Line Results from Phase 3 LYNX-2 Trial of MR-142
-
Viatris Announces Positive Top-Line Results from Phase 3 LYNX-2 Trial of MR-142 in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions
-
VTRS DEADLINE ALERT: ROSEN, LEADING INVESTOR COUNSEL, Encourages Viatris Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 3 Deadline in Securities Class Action - V
-
VTRS FINAL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Viatris Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 3 Deadline in Securities Class Action - V
-
VTRS DEADLINE: ROSEN, REGARDED INVESTOR COUNSEL, Encourages Viatris Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 3 Deadline in Securities Class Action - VTRS
-
VTRS DEADLINE NOTICE: ROSEN, A LEADING LAW FIRM, Encourages Viatris Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 3 Deadline in Securities Class Action - VTRS
-
VTRS DEADLINE NOTICE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Viatris Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 3 Deadline in Securities Class Acti
-
VTRS IMPORTANT DEADLINE: ROSEN, A LONGSTANDING LAW FIRM, Encourages Viatris Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 3 Deadline in Securities Class Action
-
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Viatris Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTRS
-
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Viatris Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTRS
-
ROSEN, A LEADING NATIONAL FIRM, Encourages Viatris Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTRS
-
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Viatris Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTRS
-
ROSEN, A LEADING LAW FIRM, Encourages Viatris Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTRS
-
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Viatris Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTRS
-
ROSEN, A LEADING LAW FIRM, Encourages Viatris Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTRS
-
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Viatris Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTRS
-
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Viatris Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTRS
-
Viatris Reports First Quarter 2025 Results and Reaffirms 2025 Outlook
-
Viatris Inc (VTRS) Reports Positive Results from Phase 3 Study of Investigational XULANE LO Low Dose Patch
-
Viatris Announces Positive Results from Phase 3 Study of Investigational XULANE LO™ Low Dose Patch for Birth Control in Women of Childbearing Potential
-
Viatris Inc (VTRS) Reports Positive Top-Line Results from Two Pivotal Phase 3 Studies of MR-107A-02
-
Viatris Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Novel Fast-Acting Meloxicam (MR-107A-02) for the Treatment of Moderate-to-Severe Acute Pain
-
ROSEN, A LEADING AND RANKED FIRM, Encourages Viatris Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTRS
-
Viatris Announces Quarterly Dividend
-
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Viatris Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTRS
-
Viatris Inc (VTRS) Appoints Frank D'Amelio and Michael Severino to its Board
-
Viatris Announces Appointments of Frank D'Amelio and Michael Severino, M.D., to the Company's Board of Directors
-
ROSEN, LEADING INVESTOR COUNSEL, Encourages Viatris Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTRS
-
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Viatris Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTRS
-
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Viatris Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTRS
-
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Viatris Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTRS
-
ROSEN, A LONGSTANDING LAW FIRM, Encourages Viatris Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTRS
-
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Viatris Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTRS
-
Viatris to Present at the BofA Securities 2025 Healthcare Conference
-
ROSEN, LEADING INVESTOR COUNSEL, Encourages Viatris Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTRS
-
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Viatris Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTRS
-
ROSEN, LEADING INVESTOR COUNSEL, Encourages Viatris Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTRS
-
Viatris Inc (VTRS) Files sNDA to Japan's Ministry of Health, Labor and Welfare for the Approval of EFFEXOR® for the Treatment of Generalized Anxiety Disorder
-
Viatris Files Supplemental New Drug Applications to Japan's Ministry of Health, Labor and Welfare for the Approval of EFFEXOR® for the Treatment of Generalized Anxiety Disorder
-
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Viatris Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTRS
-
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Viatris Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTRS
-
ROSEN, A LEADING LAW FIRM, Encourages Viatris Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTRS
-
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Viatris Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTRS
-
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Viatris Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTRS
-
Viatris Inc (VTRS) Appoints Hemanth J. Varghese as Chief Strategy Officer

